Publication: The role of syringic acid as a neuroprotective agent for neurodegenerative disorders and future expectations
| dc.contributor.author | Ogut, E. | |
| dc.contributor.author | Armagan, Kutay | |
| dc.contributor.author | Gül, Zülfiye | |
| dc.contributor.institution | Ogut, E., Department of Anatomy, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.contributor.institution | Armagan, Kutay, Medical Faculty Student, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.contributor.institution | Gül, Zülfiye, Department of Pharmacology, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.date.accessioned | 2025-10-05T15:19:16Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Hundreds of millions of people are influenced by neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), traumatic disorders of the nervous system, dementia, and various neurological disorders. Syringic acid (SA) is a natural phenolic compound that is found in medicinal herbs and dietary plants. The therapeutic potential of SA is due to its anti-oxidative, chemoprotective, anti-angiogenic, anti-glycating, anti-proliferative, anti-hyperglycaemic, anti-endotoxic, anti-microbial, anti-inflammatory, anti-diabetic and anti-depressant properties. However, in recent studies, its neuroprotective effect has drawn attention. The current review focuses on the neuroprotective bioactivities of SA and putative mechanisms of action. An electronic data search was performed using different search engines, and the relevant articles (with or without meta-analysis) with any language were selected. In the central and peripheral nervous system, SA has been shown a significant role in excitatory neurotransmitters and alleviate behavioral dysfunctions. The consensus of the literature search was that SA treatment may help neurological dysfunction or behavioral impairments management with antioxidant, anti-inflammatory properties. Furthermore, administration and proper dose of SA could be crucial factors for the effective treatment of neurological diseases. © 2022 Elsevier B.V., All rights reserved. | |
| dc.identifier.doi | 10.1007/s11011-022-00960-3 | |
| dc.identifier.endpage | 880 | |
| dc.identifier.issn | 15737365 | |
| dc.identifier.issn | 08857490 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pubmed | 35334041 | |
| dc.identifier.scopus | 2-s2.0-85127288053 | |
| dc.identifier.startpage | 859 | |
| dc.identifier.uri | https://doi.org/10.1007/s11011-022-00960-3 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14719/8839 | |
| dc.identifier.volume | 37 | |
| dc.language.iso | en | |
| dc.publisher | Springer | |
| dc.relation.source | Metabolic Brain Disease | |
| dc.subject.authorkeywords | Brain | |
| dc.subject.authorkeywords | Neurodegenerative Disorders | |
| dc.subject.authorkeywords | Neurological Diseases | |
| dc.subject.authorkeywords | Neuroprotective | |
| dc.subject.authorkeywords | Syringic Acid | |
| dc.subject.authorkeywords | Syringic Acid | |
| dc.subject.authorkeywords | Gallic Acid | |
| dc.subject.authorkeywords | Anti-inflammatory Agents | |
| dc.subject.authorkeywords | Gallic Acid | |
| dc.subject.authorkeywords | Neuroprotective Agents | |
| dc.subject.authorkeywords | Syringic Acid | |
| dc.subject.authorkeywords | Neurotransmitter | |
| dc.subject.authorkeywords | Syringic Acid | |
| dc.subject.authorkeywords | Antiinflammatory Agent | |
| dc.subject.authorkeywords | Gallic Acid | |
| dc.subject.authorkeywords | Neuroprotective Agent | |
| dc.subject.authorkeywords | Antiinflammatory Activity | |
| dc.subject.authorkeywords | Antioxidant Activity | |
| dc.subject.authorkeywords | Behavior Disorder | |
| dc.subject.authorkeywords | Central Nervous System | |
| dc.subject.authorkeywords | Degenerative Disease | |
| dc.subject.authorkeywords | Drug Mechanism | |
| dc.subject.authorkeywords | Human | |
| dc.subject.authorkeywords | Neuroprotection | |
| dc.subject.authorkeywords | Nonhuman | |
| dc.subject.authorkeywords | Peripheral Nervous System | |
| dc.subject.authorkeywords | Review | |
| dc.subject.authorkeywords | Motivation | |
| dc.subject.authorkeywords | Anti-inflammatory Agents | |
| dc.subject.authorkeywords | Gallic Acid | |
| dc.subject.authorkeywords | Humans | |
| dc.subject.authorkeywords | Motivation | |
| dc.subject.authorkeywords | Neurodegenerative Diseases | |
| dc.subject.authorkeywords | Neuroprotective Agents | |
| dc.subject.indexkeywords | neurotransmitter | |
| dc.subject.indexkeywords | syringic acid | |
| dc.subject.indexkeywords | antiinflammatory agent | |
| dc.subject.indexkeywords | gallic acid | |
| dc.subject.indexkeywords | neuroprotective agent | |
| dc.subject.indexkeywords | antiinflammatory activity | |
| dc.subject.indexkeywords | antioxidant activity | |
| dc.subject.indexkeywords | behavior disorder | |
| dc.subject.indexkeywords | central nervous system | |
| dc.subject.indexkeywords | degenerative disease | |
| dc.subject.indexkeywords | drug mechanism | |
| dc.subject.indexkeywords | human | |
| dc.subject.indexkeywords | neuroprotection | |
| dc.subject.indexkeywords | nonhuman | |
| dc.subject.indexkeywords | peripheral nervous system | |
| dc.subject.indexkeywords | Review | |
| dc.subject.indexkeywords | motivation | |
| dc.subject.indexkeywords | Anti-Inflammatory Agents | |
| dc.subject.indexkeywords | Gallic Acid | |
| dc.subject.indexkeywords | Humans | |
| dc.subject.indexkeywords | Motivation | |
| dc.subject.indexkeywords | Neurodegenerative Diseases | |
| dc.subject.indexkeywords | Neuroprotective Agents | |
| dc.title | The role of syringic acid as a neuroprotective agent for neurodegenerative disorders and future expectations | |
| dc.type | Review | |
| dcterms.references | Abaza, Mohamed Salah I., Syringic acid from Tamarix aucheriana possesses antimitogenic and chemo-sensitizing activities in human colorectal cancer cells, Pharmaceutical Biology, 51, 9, pp. 1110-1124, (2013), Arumugam, Balasubramanian, Syringic acid, a phenolic acid, promotes osteoblast differentiation by stimulation of Runx2 expression and targeting of Smad7 by miR-21 in mouse mesenchymal stem cells, Journal of Cell Communication and Signaling, 12, 3, pp. 561-573, (2018), Baǧdaş, Deniz, Pharmacologic overview of chlorogenic acid and its metabolites in chronic pain and inflammation, Current Neuropharmacology, 18, 3, pp. 216-228, (2020), Belkheiri, Nadji, Synthesis and antioxidant activity evaluation of a syringic hydrazones family, European Journal of Medicinal Chemistry, 45, 7, pp. 3019-3026, (2010), Cao, Yidong, Neuroprotective effects of syringic acid against OGD/R-induced injury in cultured hippocampal neuronal cells, International Journal of Molecular Medicine, 38, 2, pp. 567-573, (2016), Chen, Suio, Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches, Neurobiology of Aging, 17, 5, pp. 781-787, (1996), Cho, Jeongyong Young, Antimicrobial activity of 4-hydroxybenzoic acid and trans 4-hydroxycinnamic acid isolated and identified from rice hull, Bioscience, Biotechnology and Biochemistry, 62, 11, pp. 2273-2276, (1998), Çikman, Öztekin, Antioxidant activity of syringic acid prevents oxidative stress in l-arginine-induced acute pancreatitis: An experimental study on rats, International Surgery, 100, 5, pp. 891-896, (2015), Clark, Richard Af F., Cutaneous tissue repair: Basic biologic considerations. I, Journal of the American Academy of Dermatology, 13, 5, pp. 701-725, (1985), Costa, Mírian Feliciano, Eugenia aurata and Eugenia punicifolia HBK inhibit inflammatory response by reducing neutrophil adhesion, degranulation and NET release, BMC Complementary and Alternative Medicine, 16, 1, (2016) | |
| dspace.entity.type | Publication | |
| local.indexed.at | Scopus | |
| person.identifier.scopus-author-id | 56403159500 | |
| person.identifier.scopus-author-id | 57221281229 | |
| person.identifier.scopus-author-id | 56086542900 |
